Evidence map›Paper›PMID 34611495›Full record

ArticleJournal of virus eradication2021

No evidence of neuronal damage as measured by neurofilament light chain in a HIV cure study utilising a kick-and-kill approach.

Jasmini Alagaratnam, Wolfgang Stöhr, Jamie Toombs, Amanda Heslegrave, Henrik Zetterberg, Magnus Gisslén, Sarah Pett, Mark Nelson, Amanda Clarke, Nneka Nwokolo and 13 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of virus eradication, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.1field-weighted citation impact, top 55% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 12 institutions in 3 countries.

Jasmini AlagaratnamDepartment of Infectious Disease, St Mary's Hospital Campus, Imperial College London, London, W2 1NY, United Kingdom.
Wolfgang StöhrMedical Research Council Clinical Trials Unit at UCL, 90 High Holborn, Holborn, London, WC1V 6LJ, United Kingdom.
Jamie ToombsUK Dementia Research Institute at University College London, UCL Cruciform Building, Gower Street, Bloomsbury, London, WC1E 6BT, UK.
Amanda HeslegraveUK Dementia Research Institute at University College London, UCL Cruciform Building, Gower Street, Bloomsbury, London, WC1E 6BT, UK.
Henrik ZetterbergUK Dementia Research Institute at University College London, UCL Cruciform Building, Gower Street, Bloomsbury, London, WC1E 6BT, UK.
Magnus GisslénDepartment of Infectious Diseases, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Blå Stråket 5, 413 45, Göteborg, Sweden.
Sarah PettMedical Research Council Clinical Trials Unit at UCL, 90 High Holborn, Holborn, London, WC1V 6LJ, United Kingdom.
Mark NelsonDepartment of Genitourinary Medicine and HIV, Chelsea & Westminster NHS Foundation Trust, 369 Fulham Rd, Chelsea, London, SW10 9NH, UK.
Amanda ClarkeDepartment of Genitourinary Medicine and HIV, Brighton & Sussex University Hospitals NHS Trust, Kemptown, Brighton, BN2 1ES, UK.
Nneka NwokoloDepartment of Genitourinary Medicine and HIV, Chelsea & Westminster NHS Foundation Trust, 369 Fulham Rd, Chelsea, London, SW10 9NH, UK.
Margaret A JohnsonDepartment of Infection and Immunity, Royal Free Hospital, Pond Street, London, NW3 2QG, United Kingdom.
Maryam KhanDepartment of Infectious Disease, St Mary's Hospital Campus, Imperial College London, London, W2 1NY, United Kingdom.
Tomas HankeThe Jenner Institute, University of Oxford, Old Road Campus Research Build, Roosevelt Dr, Headington, Oxford, OX3 7DQ, UK.
Jakub KopycinskiNuffield Department of Medicine, University of Oxford, Oxford, OX1 2JD, UK.
Lucy DorrellNuffield Department of Medicine, University of Oxford, Oxford, OX1 2JD, UK.
Julie FoxDepartment of Genitourinary Medicine and HIV, Guy's and St Thomas' NHS Foundation Trust, Great Maze Pond, London, SE1 9RT, UK.
Sabine KinlochDepartment of Infection and Immunity, Royal Free Hospital, Pond Street, London, NW3 2QG, United Kingdom.
Jonathan UnderwoodDepartment of Infectious Disease, St Mary's Hospital Campus, Imperial College London, London, W2 1NY, United Kingdom.
Matthew PacePeter Medawar Building for Pathogen Research, Nuffield Department of Medicine, University of Oxford, South Parks Road, Oxford, OX1 3SY, UK.
John FraterPeter Medawar Building for Pathogen Research, Nuffield Department of Medicine, University of Oxford, South Parks Road, Oxford, OX1 3SY, UK.
Alan WinstonDepartment of Infectious Disease, St Mary's Hospital Campus, Imperial College London, London, W2 1NY, United Kingdom.
Sarah FidlerDepartment of Infectious Disease, St Mary's Hospital Campus, Imperial College London, London, W2 1NY, United Kingdom.
RIVER trial study group
University of Oxford · GBImperial College Healthcare NHS Trust · GBChelsea and Westminster Hospital NHS Foundation Trust · GBSahlgrenska University Hospital · SESt Mary's Hospital · GBThe Royal Free Hospital · GBUK Dementia Research Institute · GBCentral and North West London NHS Foundation Trust · GBGuy's and St Thomas' NHS Foundation Trust · GBNational Institute for Health Research · GBUniversity College London · GBUniversity Hospitals Sussex NHS Foundation Trust · GB

Funding

Medical Research Council G0701669Medical Research Council G1001757Medical Research Council MR/L00528X/1Medical Research Council MR/N023668/1
6 · The paper itself

Abstract

objectiveHIV-remission strategies including kick-and-kill could induce viral transcription and immune-activation in the central nervous system, potentially causing neuronal injury. We investigated the impact of kick-and-kill on plasma neurofilament light (NfL), a marker of neuro-axonal injury, in RIVER trial participants commencing antiretroviral treatment (ART) during primary infection and randomly allocated to ART-alone or kick-and-kill (ART + vaccination + vorinostat (ART + V + V)).

designSub-study measuring serial plasma NfL concentrations.

methodsPlasma NfL (using Simoa digital immunoassay), plasma HIV-1 RNA (using single-copy assay) and total HIV-1 DNA (using quantitative polymerase chain reaction in peripheral CD4

resultsAt randomisation, 58 male participants had median age 32 years and CD4

conclusionsDespite evidence of vaccine-induced HIV-specific T-cell responses, we observed no evidence of increased neuro-axonal injury using plasma NfL as a biomarker up to 18 weeks following kick-and-kill, compared with ART-only.

Indexed as

HIV-1 remission approachHIV-1 therapeutic vaccinationKick and killNeuro-axonal injuryNeurofilament light chain proteinVorinostat

Identifiers

PMID34611495
PMCPMC8477217
OpenAlexW3200077411

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.